Management Change/Compensation Form 8 K

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 7, 2024, the Compensation Committee of the Board of Directors of Benitec Biopharma Inc. (the "Company") approved discretionary bonus payments for Dr. Jerel Banks, the Company's Executive Chairman and Chief Executive Officer, and Megan Boston, the Company's Executive Director, in connection with their performance during the Company's fiscal year ending June 30, 2024, in the amount of $360,360 for Dr. Banks and $161,580 for Ms. Boston (Ms. Boston's bonus as reported in this Current Report on Form 8-K has beenconverted to U.S. dollars from Australian dollars using a conversion rate of AUD $1.00 to USD $0.67, which was the approximate conversion rate as of November 7, 2024).